- Home
- ATCH vs QNRX Comparison
ATCH vs QNRX Comparison
Compare ATCH & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- QNRX
- Stock Information
- Founded
- ATCH 2022
- QNRX 2018
- Country
- ATCH United States
- QNRX United States
- Employees
- ATCH N/A
- QNRX N/A
- Industry
- ATCH
- QNRX Medical/Dental Instruments
- Sector
- ATCH
- QNRX Health Care
- Exchange
- ATCH Nasdaq
- QNRX Nasdaq
- Market Cap
- ATCH 2.5M
- QNRX 2.7M
- IPO Year
- ATCH N/A
- QNRX N/A
- Fundamental
- Price
- ATCH $2.35
- QNRX $0.32
- Analyst Decision
- ATCH
- QNRX Strong Buy
- Analyst Count
- ATCH 0
- QNRX 1
- Target Price
- ATCH N/A
- QNRX $4.00
- AVG Volume (30 Days)
- ATCH 250.1K
- QNRX 4.1M
- Earning Date
- ATCH 02-19-2025
- QNRX 03-12-2025
- Dividend Yield
- ATCH N/A
- QNRX N/A
- EPS Growth
- ATCH N/A
- QNRX N/A
- EPS
- ATCH 2.67
- QNRX N/A
- Revenue
- ATCH N/A
- QNRX N/A
- Revenue This Year
- ATCH N/A
- QNRX N/A
- Revenue Next Year
- ATCH N/A
- QNRX N/A
- P/E Ratio
- ATCH $0.88
- QNRX N/A
- Revenue Growth
- ATCH N/A
- QNRX N/A
- 52 Week Low
- ATCH $1.73
- QNRX $0.28
- 52 Week High
- ATCH $209.40
- QNRX $6.18
- Technical
- Relative Strength Index (RSI)
- ATCH 23.48
- QNRX 38.39
- Support Level
- ATCH $1.73
- QNRX $0.30
- Resistance Level
- ATCH $2.40
- QNRX $0.35
- Average True Range (ATR)
- ATCH 0.60
- QNRX 0.04
- MACD
- ATCH 0.07
- QNRX 0.01
- Stochastic Oscillator
- ATCH 20.53
- QNRX 17.24
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.